Quantitative  ||| S:0 E:13 ||| NNP
Susceptibility  ||| S:13 E:28 ||| NNP
Mapping  ||| S:28 E:36 ||| NNP
of  ||| S:36 E:39 ||| IN
Intracerebral  ||| S:39 E:53 ||| NNP
Hemorrhages  ||| S:53 E:65 ||| NNP
at  ||| S:65 E:68 ||| IN
Various  ||| S:68 E:76 ||| NNP
Stages  ||| S:76 E:83 ||| NNP
To  ||| S:83 E:86 ||| TO
investigate  ||| S:86 E:98 ||| VB
the  ||| S:98 E:102 ||| DT
magnetic  ||| S:102 E:111 ||| JJ
susceptibility  ||| S:111 E:126 ||| NN
of  ||| S:126 E:129 ||| IN
intracerebral  ||| S:129 E:143 ||| JJ
hemorrhages  ||| S:143 E:155 ||| NNS
( ||| S:155 E:156 ||| -LRB-
ICH ||| S:156 E:159 ||| NNP
)  ||| S:159 E:161 ||| -RRB-
at  ||| S:161 E:164 ||| IN
various  ||| S:164 E:172 ||| JJ
stages  ||| S:172 E:179 ||| NNS
by  ||| S:179 E:182 ||| IN
applying  ||| S:182 E:191 ||| VBG
quantitative  ||| S:191 E:204 ||| JJ
susceptibility  ||| S:204 E:219 ||| JJ
mapping  ||| S:219 E:227 ||| NN
( ||| S:227 E:228 ||| -LRB-
QSM ||| S:228 E:231 ||| NNP
) ||| S:231 E:232 ||| -RRB-
.  ||| S:232 E:234 ||| .
Blood  ||| S:234 E:240 ||| NN
susceptibility  ||| S:240 E:255 ||| NNS
was  ||| S:255 E:259 ||| VBD
measured  ||| S:259 E:268 ||| VBN
serially  ||| S:268 E:277 ||| VBN
using  ||| S:277 E:283 ||| VBG
QSM  ||| S:283 E:287 ||| NNP
after  ||| S:287 E:293 ||| IN
venous  ||| S:293 E:300 ||| JJ
blood  ||| S:300 E:306 ||| NN
withdrawal  ||| S:306 E:317 ||| NN
from  ||| S:317 E:322 ||| IN
healthy  ||| S:322 E:330 ||| JJ
subjects ||| S:330 E:338 ||| NNS
.  ||| S:338 E:340 ||| .
Forty-two  ||| S:340 E:350 ||| JJ
patients  ||| S:350 E:359 ||| NNS
who  ||| S:359 E:363 ||| WP
provided  ||| S:363 E:372 ||| VBD
written  ||| S:372 E:380 ||| VBN
consent  ||| S:380 E:388 ||| NN
were  ||| S:388 E:393 ||| VBD
recruited  ||| S:393 E:403 ||| VBN
in  ||| S:403 E:406 ||| IN
this  ||| S:406 E:411 ||| DT
Institutional  ||| S:411 E:425 ||| NNP
Review  ||| S:425 E:432 ||| NNP
Board-approved  ||| S:432 E:447 ||| JJ
study ||| S:447 E:452 ||| NN
.  ||| S:452 E:454 ||| .
Gradient  ||| S:454 E:463 ||| FW
echo  ||| S:463 E:468 ||| FW
magnetic  ||| S:468 E:477 ||| FW
resonance  ||| S:477 E:487 ||| FW
imaging  ||| S:487 E:495 ||| FW
( ||| S:495 E:496 ||| -LRB-
MRI ||| S:496 E:499 ||| NNP
)  ||| S:499 E:501 ||| -RRB-
data  ||| S:501 E:506 ||| NNS
of  ||| S:506 E:509 ||| IN
the  ||| S:509 E:513 ||| DT
42  ||| S:513 E:516 ||| CD
patients  ||| S:516 E:525 ||| NNS
( ||| S:525 E:526 ||| -LRB-
17  ||| S:526 E:529 ||| CD
females ||| S:529 E:536 ||| NNS
;  ||| S:536 E:538 ||| :
64  ||| S:538 E:541 ||| CD
±  ||| S:541 E:543 ||| CD
12  ||| S:543 E:546 ||| CD
years ||| S:546 E:551 ||| NNS
)  ||| S:551 E:553 ||| -RRB-
with  ||| S:553 E:558 ||| IN
ICH  ||| S:558 E:562 ||| NNP
were  ||| S:562 E:567 ||| VBD
processed  ||| S:567 E:577 ||| VBN
with  ||| S:577 E:582 ||| IN
QSM ||| S:582 E:585 ||| NNP
.  ||| S:585 E:587 ||| .
The  ||| S:587 E:591 ||| DT
susceptibilities  ||| S:591 E:608 ||| NN
of  ||| S:608 E:611 ||| IN
various  ||| S:611 E:619 ||| JJ
blood  ||| S:619 E:625 ||| NN
products  ||| S:625 E:634 ||| NNS
within  ||| S:634 E:641 ||| IN
hematomas  ||| S:641 E:651 ||| NN
were  ||| S:651 E:656 ||| VBD
measured  ||| S:656 E:665 ||| VBN
on  ||| S:665 E:668 ||| IN
QSM ||| S:668 E:671 ||| NNP
.  ||| S:671 E:673 ||| .
Blood  ||| S:673 E:679 ||| NN
susceptibility  ||| S:679 E:694 ||| VBZ
continually  ||| S:694 E:706 ||| RB
increased  ||| S:706 E:716 ||| VBN
and  ||| S:716 E:720 ||| CC
reached  ||| S:720 E:728 ||| VBD
a  ||| S:728 E:730 ||| DT
plateau  ||| S:730 E:738 ||| NN
96  ||| S:738 E:741 ||| CD
hours  ||| S:741 E:747 ||| NNS
after  ||| S:747 E:753 ||| IN
venous  ||| S:753 E:760 ||| JJ
blood  ||| S:760 E:766 ||| NN
withdrawal ||| S:766 E:776 ||| NN
.  ||| S:776 E:778 ||| .
Hematomas  ||| S:778 E:788 ||| NNP
at  ||| S:788 E:791 ||| IN
all  ||| S:791 E:795 ||| DT
stages  ||| S:795 E:802 ||| NNS
were  ||| S:802 E:807 ||| VBD
consistently  ||| S:807 E:820 ||| RB
hyperintense  ||| S:820 E:833 ||| VBN
on  ||| S:833 E:836 ||| IN
QSM ||| S:836 E:839 ||| NNP
.  ||| S:839 E:841 ||| .
Susceptibility  ||| S:841 E:856 ||| NNP
was  ||| S:856 E:860 ||| VBD
0.57  ||| S:860 E:865 ||| CD
±  ||| S:865 E:867 ||| CD
0.48 ||| S:867 E:871 ||| CD
,  ||| S:871 E:873 ||| ,
1.30  ||| S:873 E:878 ||| NNP
±  ||| S:878 E:880 ||| NNP
0.33 ||| S:880 E:884 ||| NNP
,  ||| S:884 E:886 ||| ,
1.14  ||| S:886 E:891 ||| NNP
±  ||| S:891 E:893 ||| NNP
0.46 ||| S:893 E:897 ||| NNP
,  ||| S:897 E:899 ||| ,
0.40  ||| S:899 E:904 ||| CD
±  ||| S:904 E:906 ||| CD
0.13 ||| S:906 E:910 ||| CD
,  ||| S:910 E:912 ||| ,
and  ||| S:912 E:916 ||| CC
0.71  ||| S:916 E:921 ||| CD
±  ||| S:921 E:923 ||| CD
0.31  ||| S:923 E:928 ||| CD
ppm  ||| S:928 E:932 ||| NN
for  ||| S:932 E:936 ||| IN
hyperacute ||| S:936 E:946 ||| NN
,  ||| S:946 E:948 ||| ,
acute ||| S:948 E:953 ||| JJ
,  ||| S:953 E:955 ||| ,
early  ||| S:955 E:961 ||| JJ
subacute ||| S:961 E:969 ||| NN
,  ||| S:969 E:971 ||| ,
late  ||| S:971 E:976 ||| JJ
subacute ||| S:976 E:984 ||| NN
,  ||| S:984 E:986 ||| ,
and  ||| S:986 E:990 ||| CC
chronic  ||| S:990 E:998 ||| JJ
stages  ||| S:998 E:1005 ||| NNS
of  ||| S:1005 E:1008 ||| IN
hematomas ||| S:1008 E:1017 ||| NN
,  ||| S:1017 E:1019 ||| ,
respectively ||| S:1019 E:1031 ||| RB
.  ||| S:1031 E:1033 ||| .
The  ||| S:1033 E:1037 ||| DT
susceptibility  ||| S:1037 E:1052 ||| JJ
decrease  ||| S:1052 E:1061 ||| NN
from  ||| S:1061 E:1066 ||| IN
early  ||| S:1066 E:1072 ||| JJ
subacute  ||| S:1072 E:1081 ||| NNS
( ||| S:1081 E:1082 ||| -LRB-
1.14  ||| S:1082 E:1087 ||| FW
ppm ||| S:1087 E:1090 ||| FW
)  ||| S:1090 E:1092 ||| -RRB-
to  ||| S:1092 E:1095 ||| TO
late  ||| S:1095 E:1100 ||| JJ
subacute  ||| S:1100 E:1109 ||| NNS
( ||| S:1109 E:1110 ||| -LRB-
0.4  ||| S:1110 E:1114 ||| FW
ppm ||| S:1114 E:1117 ||| FW
)  ||| S:1117 E:1119 ||| -RRB-
was  ||| S:1119 E:1123 ||| VBD
significant  ||| S:1123 E:1135 ||| JJ
( ||| S:1135 E:1136 ||| -LRB-
P    ||| S:1136 E:1138 ||| CD
< ||| S:1138 E:1139 ||| SYM
0.01 ||| S:1140 E:1144 ||| CD
) ||| S:1144 E:1145 ||| -RRB-
.  ||| S:1145 E:1147 ||| .
QSM  ||| S:1147 E:1151 ||| NNP
reveals  ||| S:1151 E:1159 ||| VBZ
positive  ||| S:1159 E:1168 ||| JJ
susceptibility  ||| S:1168 E:1183 ||| NN
in  ||| S:1183 E:1186 ||| IN
hyperacute  ||| S:1186 E:1197 ||| JJ
hematomas ||| S:1197 E:1206 ||| NN
,  ||| S:1206 E:1208 ||| ,
indicating  ||| S:1208 E:1219 ||| VBG
that  ||| S:1219 E:1224 ||| IN
even  ||| S:1224 E:1229 ||| RB
at  ||| S:1229 E:1232 ||| IN
their  ||| S:1232 E:1238 ||| PRP$
hyperacute  ||| S:1238 E:1249 ||| JJ
stage ||| S:1249 E:1254 ||| NN
,  ||| S:1254 E:1256 ||| ,
deoxyhemoglobin  ||| S:1256 E:1272 ||| NNS
may  ||| S:1272 E:1276 ||| MD
exist  ||| S:1276 E:1282 ||| VB
throughout  ||| S:1282 E:1293 ||| IN
the  ||| S:1293 E:1297 ||| DT
hematoma  ||| S:1297 E:1306 ||| JJ
volume ||| S:1306 E:1312 ||| NN
,  ||| S:1312 E:1314 ||| ,
not  ||| S:1314 E:1318 ||| RB
just  ||| S:1318 E:1323 ||| RB
at  ||| S:1323 E:1326 ||| IN
its  ||| S:1326 E:1330 ||| PRP$
rim ||| S:1330 E:1333 ||| NN
,  ||| S:1333 E:1335 ||| ,
as  ||| S:1335 E:1338 ||| RB
seen  ||| S:1338 E:1343 ||| VBN
on  ||| S:1343 E:1346 ||| IN
conventional  ||| S:1346 E:1359 ||| JJ
T2*  ||| S:1359 E:1363 ||| CD
imaging ||| S:1363 E:1370 ||| NN
.  ||| S:1370 E:1372 ||| .
QSM  ||| S:1372 E:1376 ||| NNP
also  ||| S:1376 E:1381 ||| RB
reveals  ||| S:1381 E:1389 ||| VBZ
a  ||| S:1389 E:1391 ||| DT
reduction  ||| S:1391 E:1401 ||| NN
of  ||| S:1401 E:1404 ||| IN
susceptibility  ||| S:1404 E:1419 ||| NN
from  ||| S:1419 E:1424 ||| IN
early  ||| S:1424 E:1430 ||| JJ
subacute  ||| S:1430 E:1439 ||| NN
to  ||| S:1439 E:1442 ||| TO
late  ||| S:1442 E:1447 ||| JJ
subacute  ||| S:1447 E:1456 ||| JJ
ICH ||| S:1456 E:1459 ||| NNP
,  ||| S:1459 E:1461 ||| ,
suggesting  ||| S:1461 E:1472 ||| VBG
that  ||| S:1472 E:1477 ||| IN
methemoglobin  ||| S:1477 E:1491 ||| JJ
concentration  ||| S:1491 E:1505 ||| NN
decreases  ||| S:1505 E:1515 ||| NNS
at  ||| S:1515 E:1518 ||| IN
the  ||| S:1518 E:1522 ||| DT
late  ||| S:1522 E:1527 ||| JJ
subacute  ||| S:1527 E:1536 ||| JJ
stage ||| S:1536 E:1541 ||| NN
.  ||| S:1541 E:1543 ||| .
J.  ||| S:1543 E:1546 ||| NNP
Magn ||| S:1546 E:1550 ||| NNP
.  ||| S:1550 E:1552 ||| .
Reson ||| S:1552 E:1557 ||| NNP
.  ||| S:1557 E:1559 ||| .
Imaging  ||| S:1559 E:1567 ||| NNP
2015 ||| S:1567 E:1571 ||| CD
.  ||| S:1571 E:1573 ||| .
